LOOKS LIKE THE NEWS IS OUTyou can read the full letter on...

LOOKS LIKE THE NEWS IS OUT

you can read the full letter on Noxopharm website under investor center presentation

Chief Executive Officer Letter
Sydney, 14 June 2024
Dear Noxopharm Shareholders,
As we approach the middle of 2024, I would like to update you on the significant progress we have
made so far this year, as well as provide further insights regarding our future direction and key
milestones.
Over the past 12 months our strategy has been further refined to focus on our two preclinical
technology platforms: Chroma™ and Sofra™. We believe these programs provide a very solid basis
for building shareholder value,
Should SOF-SKN deliver the positive results we anticipate, then the world opens up for the
treatment of other autoimmune diseases like rheumatoid arthritis and many others – each one a
market of millions of people worldwide who are looking for new drugs to relieve their suffering. This
remains a huge market of unmet need.

On a final note, I would like to address the current share price, which we remain frustrated with. We
will continue to work hard to expose the company’s unique technologies to a widening audience.
This is a process that has commenced, but that takes time. Moreover, we do not believe the current
share price reflects the quality of our portfolio or the significant progress we have made.
Importantly, we remain deeply committed to driving company performance upwards as we steadily
advance our assets this year, which should result in overall improvement in investor perception.
I want to thank everyone for your ongoing support and look forward to updating you further as the
year progresses.
Kind regards,
Gisela
Dr Gisela Mautner
CEO & Managing Director
Noxopharm